1932

Abstract

Immature myeloid cells at varied stages of differentiation, known as myeloid-derived suppressor cells (MDSC), are present in virtually all cancer patients. MDSC are profoundly immune-suppressive cells that impair adaptive and innate antitumor immunity and promote tumor progression through nonimmune mechanisms. Their widespread presence combined with their multitude of protumor activities makes MDSC a major obstacle to cancer immunotherapies. MDSC are derived from progenitor cells in the bone marrow and traffic through the blood to infiltrate solid tumors. Their accumulation and suppressive potency are driven by multiple tumor- and host-secreted proinflammatory factors and adrenergic signals that act via diverse but sometimes overlapping transcriptional pathways. MDSC also accumulate in response to the chronic inflammation and lipid deposition characteristic of obesity and contribute to the more rapid progression of cancers in obese individuals. This article summarizes the key aspects of tumor-induced MDSC with a focus on recent progress in the MDSC field.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-cancerbio-042120-105240
2021-03-04
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/cancerbio/5/1/annurev-cancerbio-042120-105240.html?itemId=/content/journals/10.1146/annurev-cancerbio-042120-105240&mimeType=html&fmt=ahah

Literature Cited

  1. Al-Khami AA, Rodriguez PC, Ochoa AC 2017a. Energy metabolic pathways control the fate and function of myeloid immune cells. J. Leukoc. Biol. 102:369–80
    [Google Scholar]
  2. Al-Khami AA, Zheng L, Del Valle L, Hossain F, Wyczechowska D et al. 2017b. Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells. OncoImmunology 6:e1344804
    [Google Scholar]
  3. Alshetaiwi H, Pervolarakis N, McIntyre LL, Ma D, Nguyen Q et al. 2020. Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci. Immunol. 5:eaay6017
    [Google Scholar]
  4. Anani W, Shurin MR. 2017. Targeting myeloid-derived suppressor cells in cancer. Adv. Exp. Med. Biol. 1036:105–28
    [Google Scholar]
  5. Arman A, Auron PE. 2003. Interleukin 1 (IL-1) induces the activation of Stat3. Adv. Exp. Med. Biol. 534:297–307
    [Google Scholar]
  6. Bao Y, Mo J, Ruan L, Li G 2015. Increased monocytic CD14+HLADRlow/− myeloid-derived suppressor cells in obesity. Mol. Med. Rep. 11:2322–28
    [Google Scholar]
  7. Beury DW, Carter KA, Nelson C, Sinha P, Hanson E et al. 2016. Myeloid-derived suppressor cell survival and function are regulated by the transcription factor Nrf2. J. Immunol. 196:3470–78
    [Google Scholar]
  8. Beury DW, Parker KH, Nyandjo M, Sinha P, Carter KA, Ostrand-Rosenberg S 2014. Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors. J. Leukoc. Biol. 96:1109–18
    [Google Scholar]
  9. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB et al. 2016. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat. Commun. 7:12150
    [Google Scholar]
  10. Bronte V, Chappell DB, Apolloni E, Cabrelle A, Wang M et al. 1999. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J. Immunol. 162:5728–37
    [Google Scholar]
  11. Bronte V, Zanovello P. 2005. Regulation of immune responses by l-arginine metabolism. Nat. Rev. Immunol. 5:641–54
    [Google Scholar]
  12. Bucsek MJ, Qiao G, MacDonald CR, Giridharan T, Evans L et al. 2017. β-Adrenergic signaling in mice housed at standard temperatures suppresses an effector phenotype in CD8+ T cells and undermines checkpoint inhibitor therapy. Cancer Res 77:5639–51
    [Google Scholar]
  13. Bunt SK, Clements VK, Hanson EM, Sinha P, Ostrand-Rosenberg S 2009. Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J. Leukoc. Biol. 85:996–1004
    [Google Scholar]
  14. Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S 2006. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 176:284–90
    [Google Scholar]
  15. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S 2007. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 67:10019–26
    [Google Scholar]
  16. Burke M, Choksawangkarn W, Edwards N, Ostrand-Rosenberg S, Fenselau C 2014. Exosomes from myeloid-derived suppressor cells carry biologically active proteins. J. Proteome Res. 13:836–43
    [Google Scholar]
  17. Calle EE, Kaaks R. 2004. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 4:579–91
    [Google Scholar]
  18. Cassetta L, Baekkevold ES, Brandau S, Bujko A, Cassatella MA et al. 2019. Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates. Cancer Immunol. Immunother. 68:687–97
    [Google Scholar]
  19. Chauhan S, Danielson S, Clements V, Edwards N, Ostrand-Rosenberg S, Fenselau C 2017. Surface glycoproteins of exosomes shed by myeloid-derived suppressor cells contribute to function. J. Proteome Res. 16:238–46
    [Google Scholar]
  20. Chen J, Sun B, Zhao X, Liang D, Liu J et al. 2013. Monophosphoryl lipid A induces bone marrow precursor cells to differentiate into myeloid-derived suppressor cells. Mol. Med. Rep. 8:1074–78
    [Google Scholar]
  21. Chen S, Akbar SM, Miyake T, Abe M, Al-Mahtab M et al. 2015. Diminished immune response to vaccinations in obesity: role of myeloid-derived suppressor and other myeloid cells. Obes. Res. Clin. Pract. 9:35–44
    [Google Scholar]
  22. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S et al. 2008. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 205:2235–49
    [Google Scholar]
  23. Cheng P, Kumar V, Liu H, Youn JI, Fishman M et al. 2014. Effects of Notch signaling on regulation of myeloid cell differentiation in cancer. Cancer Res 74:141–52
    [Google Scholar]
  24. Chiribau CB, Gaccioli F, Huang CC, Yuan CL, Hatzoglou M 2010. Molecular symbiosis of CHOP and C/EBPβ isoform LIP contributes to endoplasmic reticulum stress-induced apoptosis. Mol. Cell. Biol. 30:3722–31
    [Google Scholar]
  25. Christmas BJ, Rafie CI, Hopkins AC, Scott BA, Ma HS et al. 2018. Entinostat converts immune-resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming tumor-infiltrating MDSCs. Cancer Immunol. Res. 6:1561–77
    [Google Scholar]
  26. Clavijo PE, Friedman J, Robbins Y, Moore EC, Smith E et al. 2019. Semaphorin4D inhibition improves response to immune-checkpoint blockade via attenuation of MDSC recruitment and function. Cancer Immunol. Res. 7:282–91
    [Google Scholar]
  27. Clements VK, Long T, Long R, Figley C, Smith DMC, Ostrand-Rosenberg S 2018. High fat diet and leptin promote tumor progression by inducing myeloid-derived suppressor cells. J. Leukoc. Biol. 103:395–407High-fat diet induces MDSC that drive the more rapid tumor progression in obese individuals.
    [Google Scholar]
  28. Condamine T, Dominguez GA, Youn JI, Kossenkov AV, Mony S et al. 2016. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci. Immunol. 1:aaf8943
    [Google Scholar]
  29. Condamine T, Kumar V, Ramachandran IR, Youn JI, Celis E et al. 2014. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J. Clin. Investig. 124:2626–39
    [Google Scholar]
  30. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI et al. 2010. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 207:2439–53Upregulation of MDSC NADPH oxidase drives production of MDSC immune-suppressive ROS.
    [Google Scholar]
  31. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S et al. 2009. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J. Immunol. 182:5693–701
    [Google Scholar]
  32. Cui TX, Kryczek I, Zhao L, Zhao E, Kuick R et al. 2013. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity 39:611–21
    [Google Scholar]
  33. Danelli L, Frossi B, Gri G, Mion F, Guarnotta C et al. 2015. Mast cells boost myeloid-derived suppressor cell activity and contribute to the development of tumor-favoring microenvironment. Cancer Immunol. Res. 3:85–95
    [Google Scholar]
  34. De Pergola G, Silvestris F 2013. Obesity as a major risk factor for cancer. J. Obes. 2013:291546
    [Google Scholar]
  35. Deng T, Lyon CJ, Bergin S, Caligiuri MA, Hsueh WA 2016. Obesity, inflammation, and cancer. Annu. Rev. Pathol. 11:421–49
    [Google Scholar]
  36. Di Mitri D, Toso A, Alimonti A 2015. Molecular pathways: targeting tumor-infiltrating myeloid-derived suppressor cells for cancer therapy. Clin. Cancer Res. 21:3108–12
    [Google Scholar]
  37. Di Mitri D, Toso A, Chen JJ, Sarti M, Pinton S et al. 2014. Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. Nature 515:134–37
    [Google Scholar]
  38. Doedens AL, Stockmann C, Rubinstein MP, Liao D, Zhang N et al. 2010. Macrophage expression of hypoxia-inducible factor-1α suppresses T-cell function and promotes tumor progression. Cancer Res 70:7465–75
    [Google Scholar]
  39. Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A et al. 2010. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur. J. Immunol. 40:22–35
    [Google Scholar]
  40. Donohoe CL, Lysaght J, O'Sullivan J, Reynolds JV 2016. Emerging concepts linking obesity with the hallmarks of cancer. Trends Endocrinol. Metab. 28:46–62
    [Google Scholar]
  41. Draghiciu O, Lubbers J, Nijman HW, Daemen T 2015. Myeloid derived suppressor cells—an overview of combat strategies to increase immunotherapy efficacy. OncoImmunology 4:e954829
    [Google Scholar]
  42. Dumitru CA, Moses K, Trellakis S, Lang S, Brandau S 2012. Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol. Immunother. 61:1155–67
    [Google Scholar]
  43. Elkabets M, Ribeiro VS, Dinarello CA, Ostrand-Rosenberg S, Di Santo JP et al. 2010. IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur. J. Immunol. 40:3347–57
    [Google Scholar]
  44. Ezernitchi AV, Vaknin I, Cohen-Daniel L, Levy O, Manaster E et al. 2006. TCRζ down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J. Immunol. 177:4763–72
    [Google Scholar]
  45. Fleming V, Hu X, Weber R, Nagibin V, Groth C et al. 2018. Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression. Front. Immunol. 9:398
    [Google Scholar]
  46. Flores RR, Clauson CL, Cho J, Lee BC, McGowan SJ et al. 2017. Expansion of myeloid-derived suppressor cells with aging in the bone marrow of mice through a NF-κB-dependent mechanism. Aging Cell 16:480–87
    [Google Scholar]
  47. Florez-Pollack S, Tseng LC, Kobayashi M, Hosler GA, Ariizumi K, Chong BF 2019. Expansion of myeloid-derived suppressor cells in the peripheral blood and lesional skin of cutaneous lupus patients. J. Investig. Dermatol. 139:478–81
    [Google Scholar]
  48. Font-Burgada J, Sun B, Karin M 2016. Obesity and cancer: the oil that feeds the flame. Cell Metab 23:48–62
    [Google Scholar]
  49. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G et al. 2009. Polarization of tumor-associated neutrophil phenotype by TGF-β: “N1” versus “N2” TAN. Cancer Cell 16:183–94
    [Google Scholar]
  50. Fujita K, Hayashi T, Matsushita M, Uemura M, Nonomura N 2019. Obesity, inflammation, and prostate cancer. J. Clin. Med. 8:2201
    [Google Scholar]
  51. Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A et al. 2007. The terminology issue for myeloid-derived suppressor cells. Cancer Res 67:425
    [Google Scholar]
  52. Gama L, Shirk EN, Russell JN, Carvalho KI, Li M et al. 2012. Expansion of a subset of CD14highCD16negCCR2low/neg monocytes functionally similar to myeloid-derived suppressor cells during SIV and HIV infection. J. Leukoc. Biol. 91:803–16
    [Google Scholar]
  53. Geis-Asteggiante L, Belew AT, Clements VK, Edwards NJ, Ostrand-Rosenberg S et al. 2018. Differential content of proteins, mRNAs, and miRNAs suggests that MDSC and their exosomes may mediate distinct immune suppressive functions. J. Proteome Res. 17:486–98
    [Google Scholar]
  54. Grauers Wiktorin H, Nilsson MS, Kiffin R, Sander FE, Lenox B et al. 2019. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade. Cancer Immunol. Immunother. 68:163–74
    [Google Scholar]
  55. Halaby MJ, Hezaveh K, Lamorte S, Ciudad MT, Kloetgen A et al. 2019. GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment. Sci. Immunol 4:eaax8189
    [Google Scholar]
  56. Hale M, Itani F, Buchta CM, Wald G, Bing M, Norian LA 2015. Obesity triggers enhanced MDSC accumulation in murine renal tumors via elevated local production of CCL2. PLOS ONE 10:e0118784
    [Google Scholar]
  57. Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S 2009. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J. Immunol. 183:937–44
    [Google Scholar]
  58. Herber DL, Cao W, Nefedova Y, Novitskiy SV, Nagaraj S et al. 2010. Lipid accumulation and dendritic cell dysfunction in cancer. Nat. Med. 16:880–86
    [Google Scholar]
  59. Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H et al. 2014. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci. Transl. Med. 6:237ra67MDSC are responsible for some of the limited efficacy of checkpoint blockade immunotherapy.
    [Google Scholar]
  60. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C et al. 2008. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+CD25+Foxp3+ T cells. Gastroenterology 135:234–43
    [Google Scholar]
  61. Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F et al. 2009. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 50:799–807
    [Google Scholar]
  62. Horikawa N, Abiko K, Matsumura N, Baba T, Hamanishi J et al. 2020. Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment. Br. J. Cancer 122:778–88
    [Google Scholar]
  63. Hossain F, Al-Khami AA, Wyczechowska D, Hernandez C, Zheng L et al. 2015. Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. Cancer Immunol. Res. 3:1236–47Fatty acid uptake and increased fatty acid oxidation amplify the suppressive potency of MDSC.
    [Google Scholar]
  64. Hu CE, Gan J, Zhang RD, Cheng YR, Huang GJ 2011. Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function. Scand. J. Gastroenterol. 46:156–64
    [Google Scholar]
  65. Huang B, Pan PY, Li Q, Sato AI, Levy DE et al. 2006. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66:1123–31
    [Google Scholar]
  66. Iyengar NM, Hudis CA, Dannenberg AJ 2015. Obesity and cancer: local and systemic mechanisms. Annu. Rev. Med. 66:297–309
    [Google Scholar]
  67. Kim K, Skora AD, Li Z, Liu Q, Tam AJ et al. 2014. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. PNAS 111:11774–79
    [Google Scholar]
  68. Kimura T, McKolanis JR, Dzubinski LA, Islam K, Potter DM et al. 2013. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev. Res. 6:18–26
    [Google Scholar]
  69. Kokkola Andersson A, Mullins G, Ostberg T, Treutiger C-J et al. 2005. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand. J. Immunol. 61:1–9
    [Google Scholar]
  70. Kokolus KM, Capitano ML, Lee CT, Eng JW, Waight JD et al. 2013. Baseline tumor growth and immune control in laboratory mice are significantly influenced by subthermoneutral housing temperature. PNAS 110:20176–81
    [Google Scholar]
  71. Kolb R, Kluz P, Tan ZW, Borcherding N, Bormann N et al. 2019. Obesity-associated inflammation promotes angiogenesis and breast cancer via angiopoietin-like 4. Oncogene 38:2351–63
    [Google Scholar]
  72. Kolb R, Sutterwala FS, Zhang W 2016. Obesity and cancer: inflammation bridges the two. Curr. Opin. Pharmacol. 29:77–89
    [Google Scholar]
  73. Kontaki E, Boumpas DT, Tzardi M, Mouzas IA, Papadakis KA, Verginis P 2017. Aberrant function of myeloid-derived suppressor cells (MDSCs) in experimental colitis and in inflammatory bowel disease (IBD) immune responses. Autoimmunity 50:170–81
    [Google Scholar]
  74. Kostlin N, Kugel H, Spring B, Leiber A, Marme A et al. 2014. Granulocytic myeloid derived suppressor cells expand in human pregnancy and modulate T-cell responses. Eur. J. Immunol. 44:2582–91
    [Google Scholar]
  75. Kowanetz M, Wu X, Lee J, Tan M, Hagenbeek T et al. 2010. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. PNAS 107:21248–55
    [Google Scholar]
  76. Ku AW, Muhitch JB, Powers CA, Diehl M, Kim M et al. 2016. Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes. eLife 5:e17375
    [Google Scholar]
  77. Kumar S, Wilkes DW, Samuel N, Blanco MA, Nayak A et al. 2018. ΔNp63-driven recruitment of myeloid-derived suppressor cells promotes metastasis in triple-negative breast cancer. J. Clin. Investig. 128:5095–109
    [Google Scholar]
  78. Lang S, Bruderek K, Kaspar C, Hoing B, Kanaan O et al. 2018. Clinical relevance and suppressive capacity of human myeloid-derived suppressor cell subsets. Clin. Cancer Res. 24:4834–44
    [Google Scholar]
  79. Law AMK, Valdes-Mora F, Gallego-Ortega D 2020. Myeloid-derived suppressor cells as a therapeutic target for cancer. Cells 9:3561
    [Google Scholar]
  80. Lee BR, Chang SY, Hong EH, Kwon BE, Kim HM et al. 2014. Elevated endoplasmic reticulum stress reinforced immunosuppression in the tumor microenvironment via myeloid-derived suppressor cells. Oncotarget 5:12331–45
    [Google Scholar]
  81. Li W, Tanikawa T, Kryczek I, Xia H, Li G et al. 2018. Aerobic glycolysis controls myeloid-derived suppressor cells and tumor immunity via a specific CEBPB isoform in triple-negative breast cancer. Cell Metab 28:87–103.e6
    [Google Scholar]
  82. Liu C, Yu S, Kappes J, Wang J, Grizzle WE et al. 2007. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 109:4336–42
    [Google Scholar]
  83. Loeuillard E, Yang J, Buckarma E, Wang J, Liu Y et al. 2020. Targeting tumor-associated macrophages and granulocytic-myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. J Clin. Investig. 130:538096
    [Google Scholar]
  84. Lu T, Ramakrishnan R, Altiok S, Youn JI, Cheng P et al. 2011. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J. Clin. Investig. 121:4015–29
    [Google Scholar]
  85. Ma P, Beatty PL, McKolanis J, Brand R, Schoen RE, Finn OJ 2019. Circulating myeloid derived suppressor cells (MDSC) that accumulate in premalignancy share phenotypic and functional characteristics with MDSC in cancer. Front. Immunol. 10:1401
    [Google Scholar]
  86. Magcwebeba T, Dorhoi A, du Plessis N 2019. The emerging role of myeloid-derived suppressor cells in tuberculosis. Front. Immunol. 10:917
    [Google Scholar]
  87. Makarenkova VP, Bansal V, Matta BM, Perez LA, Ochoa JB 2006. CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J. Immunol. 176:2085–94
    [Google Scholar]
  88. Maltby S, Khazaie K, McNagny KM 2009. Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim. Biophys. Acta 1796:19–26
    [Google Scholar]
  89. Mao Y, Poschke I, Wennerberg E, Pico de Coana Y, Egyhazi Brage S et al. 2013. Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res 73:3877–87
    [Google Scholar]
  90. Mao Y, Sarhan D, Steven A, Seliger B, Kiessling R, Lundqvist A 2014. Inhibition of tumor-derived prostaglandin-E2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clin. Cancer Res. 20:4096–106
    [Google Scholar]
  91. Marigo I, Bosio E, Solito S, Mesa C, Fernandez A et al. 2010. Tumor-induced tolerance and immune suppression depend on the C/EBPβ transcription factor. Immunity 32:790–802ER stress pathway is a major regulator of MDSC (also Thevenot et al. 2014).
    [Google Scholar]
  92. Mohammadpour H, MacDonald CR, Qiao G, Chen M, Dong B et al. 2019. β2 adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells. J. Clin. Investig. 129:5537–52External stress in the form of the catecholamine norepinephrine stimulates MDSC suppressive activity.
    [Google Scholar]
  93. Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S et al. 2011. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J. Exp. Med. 208:1949–62
    [Google Scholar]
  94. Morales JK, Saleem SJ, Martin RK, Saunders BL, Barnstein BO et al. 2014. Myeloid-derived suppressor cells enhance IgE-mediated mast cell responses. J. Leukoc. Biol. 95:643–50
    [Google Scholar]
  95. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C et al. 2008. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111:4233–44MDSC consist of two subtypes: mononuclear MDSC (M-MDSC) and polymorphonuclear/granular MDSC (PMN-MDSC).
    [Google Scholar]
  96. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S et al. 2007. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 13:828–35
    [Google Scholar]
  97. Nakajima K, Yamanaka Y, Nakae K, Kojima H, Ichiba M et al. 1996. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J 15:3651–58
    [Google Scholar]
  98. Nakamura T, Ushigome H. 2018. Myeloid-derived suppressor cells as a regulator of immunity in organ transplantation. Int. J. Mol. Sci. 19:2357
    [Google Scholar]
  99. Nefedova Y, Cheng P, Gilkes D, Blaskovich M, Beg AA et al. 2005a. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J. Immunol. 175:4338–46
    [Google Scholar]
  100. Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI 2005b. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the Janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res 65:9525–35
    [Google Scholar]
  101. Netherby CS, Abrams SI. 2017. Mechanisms overseeing myeloid-derived suppressor cell production in neoplastic disease. Cancer Immunol. Immunother. 66:989–96
    [Google Scholar]
  102. Netherby CS, Messmer MN, Burkard-Mandel L, Colligan S, Miller A et al. 2017. The granulocyte progenitor stage is a key target of IRF8-mediated regulation of myeloid-derived suppressor cell production. J. Immunol. 198:4129–39
    [Google Scholar]
  103. O'Connor MA, Rastad JL, Green WR 2017. The role of myeloid-derived suppressor cells in viral infection. Viral Immunol 30:82–97
    [Google Scholar]
  104. Okazaki T, Ebihara S, Asada M, Kanda A, Sasaki H, Yamaya M 2006. Granulocyte colony-stimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models. Int. Immunol. 18:1–9
    [Google Scholar]
  105. Okwan-Duodu D, Umpierrez GE, Brawley OW, Diaz R 2013. Obesity-driven inflammation and cancer risk: role of myeloid derived suppressor cells and alternately activated macrophages. Am. J. Cancer Res. 3:21–33
    [Google Scholar]
  106. Orillion A, Hashimoto A, Damayanti N, Shen L, Adelaiye-Ogala R et al. 2017. Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma. Clin. Cancer Res. 23:5187–201
    [Google Scholar]
  107. Ortiz ML, Kumar V, Martner A, Mony S, Donthireddy L et al. 2015. Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17-producing CD4+ T cells. J. Exp. Med. 212:351–67
    [Google Scholar]
  108. Ost M, Singh A, Peschel A, Mehling R, Rieber N, Hartl D 2016. Myeloid-derived suppressor cells in bacterial infections. Front. Cell Infect. Microbiol. 6:37
    [Google Scholar]
  109. Ostrand-Rosenberg S, Sinha P. 2009. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182:4499–506
    [Google Scholar]
  110. Ostrand-Rosenberg S, Sinha P, Figley C, Long R, Park D et al. 2017. Myeloid-derived suppressor cells (MDSCs) facilitate maternal-fetal tolerance in mice. J. Leukoc. Biol. 101:1091–101
    [Google Scholar]
  111. Pan PY, Ma G, Weber KJ, Ozao-Choy J, Wang G et al. 2010. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 70:99–108
    [Google Scholar]
  112. Pan T, Liu Y, Zhong LM, Shi MH, Duan XB et al. 2016. Myeloid-derived suppressor cells are essential for maintaining feto-maternal immunotolerance via STAT3 signaling in mice. J. Leukoc. Biol. 100:499–511
    [Google Scholar]
  113. Papaspyridonos M, Matei I, Huang Y, do Rosario Andre M, Brazier-Mitouart H et al. 2015. Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation. Nat. Commun. 6:6840
    [Google Scholar]
  114. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D et al. 2004. Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279:7370–77
    [Google Scholar]
  115. Park SM, Youn JI. 2019. Role of myeloid-derived suppressor cells in immune checkpoint inhibitor therapy in cancer. Arch. Pharm. Res. 42:560–66
    [Google Scholar]
  116. Parker KH, Beury DW, Ostrand-Rosenberg S 2015. Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment. Adv. Cancer Res. 128:95–139
    [Google Scholar]
  117. Parker KH, Horn LA, Ostrand-Rosenberg S 2016. High-mobility group box protein 1 promotes the survival of myeloid-derived suppressor cells by inducing autophagy. J. Leukoc. Biol. 100:463–70
    [Google Scholar]
  118. Parker KH, Sinha P, Horn LA, Clements VK, Yang H et al. 2014. HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. Cancer Res 74:5723–33
    [Google Scholar]
  119. Pawelec G, Verschoor CP, Ostrand-Rosenberg S 2019. Myeloid-derived suppressor cells: not only in tumor immunity. Front. Immunol. 10:1099
    [Google Scholar]
  120. Peranzoni E, Ingangi V, Masetto E, Pinton L, Marigo I 2020. Myeloid cells as clinical biomarkers for immune checkpoint blockade. Front. Immunol. 11:1590
    [Google Scholar]
  121. Raber P, Ochoa AC, Rodriguez PC 2012. Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol. Investig. 41:614–34
    [Google Scholar]
  122. Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J et al. 2005. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J. Exp. Med. 202:931–39
    [Google Scholar]
  123. Sade-Feldman M, Kanterman J, Ish-Shalom E, Elnekave M, Horwitz E, Baniyash M 2013. Tumor necrosis factor-α blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity 38:541–54
    [Google Scholar]
  124. Sagiv JY, Michaeli J, Assi S, Mishalian I, Kisos H et al. 2015. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell Rep 10:562–73
    [Google Scholar]
  125. Salminen A, Kauppinen A, Kaarniranta K 2019. AMPK activation inhibits the functions of myeloid-derived suppressor cells (MDSC): impact on cancer and aging. J. Mol. Med. 97:1049–64
    [Google Scholar]
  126. Schmielau J, Finn OJ. 2001. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 61:4756–60
    [Google Scholar]
  127. Schrijver IT, Theroude C, Roger T 2019. Myeloid-derived suppressor cells in sepsis. Front. Immunol. 10:327
    [Google Scholar]
  128. Serafini P, Mgebroff S, Noonan K, Borrello I 2008. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 68:5439–49
    [Google Scholar]
  129. Shojaei F, Wu X, Qu X, Kowanetz M, Yu L et al. 2009. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. PNAS 106:6742–47
    [Google Scholar]
  130. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S 2007a. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 179:977–83
    [Google Scholar]
  131. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S 2007b. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 67:4507–13PGE2 is an inducer and effector of MDSC (also Mao et al. 2014, Rodriguez et al. 2005).
    [Google Scholar]
  132. Sinha P, Clements VK, Ostrand-Rosenberg S 2005. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res 65:11743–51
    [Google Scholar]
  133. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G 2008. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J. Immunol. 181:4666–75
    [Google Scholar]
  134. Song X, Krelin Y, Dvorkin T, Bjorkdahl O, Segal S et al. 2005. CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1β-secreting cells. J. Immunol. 175:8200–8
    [Google Scholar]
  135. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S 2010. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 70:68–77
    [Google Scholar]
  136. Stewart TJ, Liewehr DJ, Steinberg SM, Greeneltch KM, Abrams SI 2009. Modulating the expression of IFN regulatory factor 8 alters the protumorigenic behavior of CD11b+Gr-1+ myeloid cells. J. Immunol. 183:117–28
    [Google Scholar]
  137. Strauss L, Sangaletti S, Consonni FM, Szebeni G, Morlacchi S et al. 2015. RORC1 regulates tumor-promoting “emergency” granulo-monocytopoiesis. Cancer Cell 28:253–69
    [Google Scholar]
  138. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM 2005. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11:6713–21
    [Google Scholar]
  139. Tavazoie MF, Pollack I, Tanqueco R, Ostendorf BN, Reis BS et al. 2018. LXR/ApoE activation restricts innate immune suppression in cancer. Cell 172:825–40.e18
    [Google Scholar]
  140. Thevenot PT, Sierra RA, Raber PL, Al-Khami AA, Trillo-Tinoco J et al. 2014. The stress-response sensor Chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors. Immunity 41:389–401
    [Google Scholar]
  141. Tobin RP, Jordan KR, Robinson WA, Davis D, Borges VF et al. 2018. Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with ipilimumab. Int. Immunopharmacol. 63:282–91
    [Google Scholar]
  142. Toh B, Wang X, Keeble J, Sim WJ, Khoo K et al. 2011. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLOS Biol 9:e1001162
    [Google Scholar]
  143. Trillo-Tinoco J, Sierra RA, Mohamed E, Cao Y, de Mingo-Pulido A et al. 2019. AMPK alpha-1 intrinsically regulates the function and differentiation of tumor myeloid-derived suppressor cells. Cancer Res 79:5034–47
    [Google Scholar]
  144. Tsukamoto H, Nishikata R, Senju S, Nishimura Y 2013. Myeloid-derived suppressor cells attenuate TH1 development through IL-6 production to promote tumor progression. Cancer Immunol. Res. 1:64–76
    [Google Scholar]
  145. Turbitt WJ, Collins SD, Meng H, Rogers CJ 2019. Increased adiposity enhances the accumulation of MDSCs in the tumor microenvironment and adipose tissue of pancreatic tumor-bearing mice and in immune organs of tumor-free hosts. Nutrients 11:3012
    [Google Scholar]
  146. Umansky V, Blattner C, Fleming V, Hu X, Gebhardt C et al. 2017. Myeloid-derived suppressor cells and tumor escape from immune surveillance. Semin. Immunopathol. 39:295–305
    [Google Scholar]
  147. Veglia F, Tyurin VA, Blasi M, De Leo A, Kossenkov AV et al. 2019. Fatty acid transport protein 2 reprograms neutrophils in cancer. Nature 569:73–78GM-CSF increases PMN-MDSC FATP2, which increases MDSC production of prostaglandin E2 and MDSC suppressive potency.
    [Google Scholar]
  148. Verschoor CP, Johnstone J, Millar J, Dorrington MG, Habibagahi M et al. 2013. Blood CD33(+)HLA-DR(−) myeloid-derived suppressor cells are increased with age and a history of cancer. J. Leukoc. Biol. 93:633–37
    [Google Scholar]
  149. Wagner NB, Weide B, Gries M, Reith M, Tarnanidis K et al. 2019. Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies. J. Immunother. Cancer 7:343
    [Google Scholar]
  150. Waight JD, Hu Q, Miller A, Liu S, Abrams SI 2011. Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLOS ONE 6:e27690
    [Google Scholar]
  151. Waight JD, Netherby C, Hensen ML, Miller A, Hu Q et al. 2013. Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J. Clin. Investig. 123:4464–78Inhibition of interferon regulatory factor 8 in common myeloid progenitor cells switches myelopoiesis to MDSC generation.
    [Google Scholar]
  152. Wang L, Zhao J, Ren JP, Wu XY, Morrison ZD et al. 2016. Expansion of myeloid-derived suppressor cells promotes differentiation of regulatory T cells in HIV-1+ individuals. AIDS 30:1521–31
    [Google Scholar]
  153. Wang Y, Schafer CC, Hough KP, Tousif S, Duncan SR et al. 2018. Myeloid-derived suppressor cells impair B cell responses in lung cancer through IL-7 and STAT5. J. Immunol. 201:278–95
    [Google Scholar]
  154. Xia S, Sha H, Yang L, Ji Y, Ostrand-Rosenberg S, Qi L 2011. Gr-1+ CD11b+ myeloid-derived suppressor cells suppress inflammation and promote insulin sensitivity in obesity. J. Biol. Chem. 286:23591–99
    [Google Scholar]
  155. Xiang H, Ramil CP, Hai J, Zhang C, Wang H et al. 2020. Cancer-associated fibroblasts promote immunosuppression by inducing ROS-generating monocytic MDSCs in lung squamous cell carcinoma. Cancer Immunol. Res. 8:4436–50
    [Google Scholar]
  156. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H 2009. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 69:2506–13
    [Google Scholar]
  157. Yan D, Yang Q, Shi M, Zhong L, Wu C et al. 2013. Polyunsaturated fatty acids promote the expansion of myeloid-derived suppressor cells by activating the JAK/STAT3 pathway. Eur. J. Immunol. 43:2943–55
    [Google Scholar]
  158. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B et al. 2004. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6:409–21
    [Google Scholar]
  159. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI 2008. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181:5791–802
    [Google Scholar]
  160. Yu J, Du W, Yan F, Wang Y, Li H et al. 2013. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J. Immunol. 190:3783–97
    [Google Scholar]
  161. Zhang H, Wang S, Huang Y, Wang H, Zhao J et al. 2015. Myeloid-derived suppressor cells are proinflammatory and regulate collagen-induced arthritis through manipulating Th17 cell differentiation. Clin. Immunol. 157:175–86
    [Google Scholar]
/content/journals/10.1146/annurev-cancerbio-042120-105240
Loading
/content/journals/10.1146/annurev-cancerbio-042120-105240
Loading

Data & Media loading...

Supplemental Material

Supplementary Data

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error